SynthesisMedical oncology (Northwood, London, England)2010
TGFB1 509 C/T polymorphism and colorectal cancer risk: a meta-analysis.
Synthesis in Medical oncology (Northwood, London, England), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Ethnic background and genetic variation in the evaluation of cancer risk: a systematic review.PloS one · 2014Pooled it
- Meta-analyses of the associations between four common TGF-β1 genetic polymorphisms and risk of colorectal tumor.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2012Pooled it
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transforming growth factor β (TGF-β) is a cytokine. The TGF-β signaling pathway plays an important role in controlling cell proliferation and differentiation involved in colorectal carcinogenesis. In mammalian cells, TGFB1 is the most abundant subtype of TGF-β. The 509 C/T polymorphism in TGFB1 has been implicated in colorectal cancer risk. However, published data remain conflicting. To derive a more precise estimation of the relationship, a meta-analysis of 994 cases and 2,335 controls from five published case-control studies was performed. Overall, significantly increased colorectal cancer risks were found for CC versus TT (OR=1.62; 95% CI: 1.30-2.02; Pheterogeneity=0.118), TC+CC versus TT (OR=1.30; 95% CI: 1.08-1.58; Pheterogeneity=0.259) and CC versus TC+TT (OR=1.48; 95% CI: 1.26-1.75; Pheterogeneity=0.244). In the subgroup analysis by ethnicity, significantly increased risks were also found among Asians for CC versus TT (OR=1.77; 95% CI: 1.40-2.24; Pheterogeneity=0.519), TC+CC versus TT (OR=1.38; 95% CI: 1.13-1.68; Pheterogeneity=0.679) and CC versus TC+TT (OR=1.58; 95% CI: 1.31-1.89; Pheterogeneity=0.340). However, no significant associations were found among Europeans for all genetic models. This meta-analysis showed that TGFB1 509 C allele is a risk factor for developing colorectal cancer in Asians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.